Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference

Terns Pharmaceuticals (Nasdaq: TERN) is set to participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference on January 18, 2023, at 2:30 p.m. ET.

Rhea-AI Summary

Terns Pharmaceuticals (Nasdaq: TERN) is set to participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference on January 18, 2023, at 2:30 p.m. ET. The event will emphasize the company's efforts in developing small-molecule therapies for serious diseases, including oncology, obesity, and non-alcoholic steatohepatitis (NASH). A live audio webcast will be accessible on Terns' investor relations page, with a replay available for 30 days afterward.

Argus Session date unavailable

+0.44% session move Open Argus

Details

News Market Reaction – TERN

The recorded move for TERN in the trading session of this news was +0.44%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FOSTER CITY, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat at the B. Riley Securities 3^rd Annual Oncology Conference on Wednesday, January 18, 2023 at 2:30 p.m. ET.

A live audio webcast of the event will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the event.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns’ pipeline includes four clinical stage development programs including an allosteric BCR-ABL inhibitor, a THR-β agonist, an FXR agonist, a VAP-1 inhibitor, and preclinical small-molecule GLP-1 receptor agonist and GIPR modulator programs. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Terns Pharmaceuticals participating in the B. Riley Securities Oncology Conference?

Terns Pharmaceuticals will participate in the B. Riley Securities 3rd Annual Oncology Conference on January 18, 2023, at 2:30 p.m. ET.

Where can I find the live webcast for the Terns Pharmaceuticals event?

The live audio webcast for the Terns Pharmaceuticals event will be available on their investor relations page at http://ir.ternspharma.com.

What is the focus of Terns Pharmaceuticals' research and development?

Terns Pharmaceuticals focuses on developing small-molecule product candidates for serious diseases, including oncology, obesity, and non-alcoholic steatohepatitis (NASH).

How long will the Terns Pharmaceuticals webcast be available for replay?

The webcast will be archived on Terns' website for 30 days following the event.

What pipeline programs does Terns Pharmaceuticals have?

Terns Pharmaceuticals has several pipeline programs, including an allosteric BCR-ABL inhibitor, a THR-β agonist, an FXR agonist, and a VAP-1 inhibitor, among others.